Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (271-280 of 477) with videos related to

Pageof 48
Sort By:
Annals of the Rheumatic Diseases|February 12, 2016
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritisCharles Peterfy, Gerd R Burmester, Vivian P Bykerk, et al.
American Journal of Respiratory and Critical Care Medicine|November 4, 2017
Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Suzanne Kafaja, Philip J Clements, Holly Wilhalme, et al.
Arthritis Research & Therapy|December 26, 2015
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trialsDinesh Khanna, Vivek Nagaraja, Chi-Hong Tseng, et al.
Rheumatology (Oxford, England)|February 19, 2013
Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trialMittie K Doyle, Mahboob U Rahman, Bart Frederick, et al.
The Journal of Rheumatology|March 3, 2011
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trialEdward C Keystone, Jeffrey R Curtis, Roy M Fleischmann, et al.
The Journal of Rheumatology|June 7, 2007
Outcome evaluations in goutH Ralph Schumacher, William Taylor, Nancy Joseph-Ridge, et al.
Seminars in Arthritis and Rheumatism|November 7, 2018
Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trialsSimon Tarp, Tanja S Jørgensen, Daniel E Furst, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|May 28, 2011
Double-blind, randomized, controlled, pilot study comparing classic ayurvedic medicine, methotrexate, and their combination in rheumatoid arthritisDaniel E Furst, Manorama M Venkatraman, Mary McGann, et al.
Arthritis and Rheumatism|May 7, 2011
Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung diseaseMichael D Roth, Chi-Hong Tseng, Philip J Clements, et al.
Arthritis and Rheumatism|May 28, 2011
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo GroupDinesh Khanna, Chi-Hong Tseng, Niloofar Farmani, et al.
Pageof 48

Showing results (271-280 of 477) with videos related to

Sort By:
Pageof 48
Annals of the Rheumatic Diseases|February 12, 2016
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritisCharles Peterfy, Gerd R Burmester, Vivian P Bykerk, et al.
American Journal of Respiratory and Critical Care Medicine|November 4, 2017
Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Suzanne Kafaja, Philip J Clements, Holly Wilhalme, et al.
Arthritis Research & Therapy|December 26, 2015
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trialsDinesh Khanna, Vivek Nagaraja, Chi-Hong Tseng, et al.
Rheumatology (Oxford, England)|February 19, 2013
Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trialMittie K Doyle, Mahboob U Rahman, Bart Frederick, et al.
The Journal of Rheumatology|March 3, 2011
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trialEdward C Keystone, Jeffrey R Curtis, Roy M Fleischmann, et al.
The Journal of Rheumatology|June 7, 2007
Outcome evaluations in goutH Ralph Schumacher, William Taylor, Nancy Joseph-Ridge, et al.
Seminars in Arthritis and Rheumatism|November 7, 2018
Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trialsSimon Tarp, Tanja S Jørgensen, Daniel E Furst, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|May 28, 2011
Double-blind, randomized, controlled, pilot study comparing classic ayurvedic medicine, methotrexate, and their combination in rheumatoid arthritisDaniel E Furst, Manorama M Venkatraman, Mary McGann, et al.
Arthritis and Rheumatism|May 7, 2011
Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung diseaseMichael D Roth, Chi-Hong Tseng, Philip J Clements, et al.
Arthritis and Rheumatism|May 28, 2011
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo GroupDinesh Khanna, Chi-Hong Tseng, Niloofar Farmani, et al.
Pageof 48